BRCA1/2致病变异者预防性乳房切除术后生存:网络Meta分析
该网络Meta分析纳入5项观察性研究共7937例BRCA1/2致病变异女性,在调整输卵管卵巢切除术后比较预防性乳房切除与MRI筛查或单独钼靶的生存差异。预防性乳房切除与较低的全因死亡率相关,在BRCA1携带者中乳腺癌特异性死亡率的关联幅度最大。证据确定性极低。
要点
- BRCA1/2致病变异女性中,预防性乳房切除较MRI筛查或单独钼靶与更低全因死亡率相关。
- BRCA1携带者中预防性乳房切除与乳腺癌特异性死亡率降低的关联幅度最大。
- 证据确定性极低,结果需结合个体化共享决策解读。
诊断标准与关键数值
- 预防性乳房切除对比MRI筛查的全因死亡率HR为0.37(95%CI 0.22-0.63)。
- 预防性乳房切除对比单独钼靶的全因死亡率HR为0.16(95%CI 0.08-0.32)。
- 预防性乳房切除对比单独钼靶的乳腺癌特异性死亡率HR为0.07(95%CI 0.01-0.44)。
- 预防性乳房切除对比MRI筛查的乳腺癌特异性死亡率HR为0.26(95%CI 0.05-1.35),差异无统计学意义。
- BRCA1-only分析中,预防性乳房切除对比MRI筛查的乳腺癌特异性死亡率HR为0.13(95%CI 0.03-0.66),对比单独钼靶HR为0.03(95%CI 0.00-0.15)。
临床应用与阅片要点
- 阅片和报告中可引用本分析提示的预防性乳房切除与生存关联,但须注明证据确定性极低。
- BRCA1携带者中预防性乳房切除与乳腺癌特异性死亡率降低的关联幅度最大,可作为共享决策参考。
- MRI筛查仍为未手术BRCA1/2携带者的重要监测手段,本分析未否定其筛查价值。
局限性
- 仅纳入5项观察性研究,4项偏倚风险为关键级别,全部证据确定性评级为极低。
- 研究数量少且样本量有限,网络Meta分析结果受混杂和选择偏倚影响。
- 部分年龄数据报告不全,仅BRCA1亚组进行了敏感性分析。
英文原文(摘要)· 点击展开
JAMA Netw Open. 2026 Oct 1;9(10):e2641231. doi: 10.1001/jamanetworkopen.2026.41231. ABSTRACT IMPORTANCE: The independent survival benefit of risk-reducing mastectomy (RRM), separate from risk-reducing salpingo-oophorectomy (RRSO), remains uncertain among patients with pathogenic variants (PVs) in BRCA1 and BRCA2 genes. OBJECTIVE: To evaluate the association of RRM, magnetic resonance imaging (MRI)-based screening, and mammography alone with all-cause and breast cancer-specific mortality using RRSO-adjusted estimates. DATA SOURCES: MEDLINE, Embase, and Web of Science were searched from January 1, 1990, to May 28, 2026. Search structures, subject headings, and keywords were tailored to each database. STUDY SELECTION: Inclusion criteria were English-language prospective and retrospective observational studies of adult female patients with PV or likely PV in BRCA1 and BRCA2 who underwent RRM or breast cancer screening (MRI-based with or without mammography, or mammography alone), with RRSO excluded by design or adjusted for in multivariable analysis. Studies including females with prior breast or ovarian cancer were excluded. DATA EXTRACTION AND SYNTHESIS: Study reporting followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 network meta-analysis extension. Two authors independently performed study selection, data extraction, and bias assessment using a risk-of-bias assessment tool (ROBINS-I V2) and a grading approach (Grading of Recommendations Assessment, Development, and Evaluation [GRADE]). Frequentist random-effects network meta-analysis was performed with surface under the cumulative ranking curve (SUCRA) estimation. Sensitivity analysis was conducted for the BRCA1 cohort. MAIN OUTCOMES AND MEASURES: Primary outcome was all-cause mortality. Secondary outcome was breast cancer-specific mortality. All outcomes were analyzed and reported as hazard ratios (HRs) with corresponding 95% CIs. RESULTS: Five observational studies with 7937 female patients (median [range] age, 35.9 [unreported] years to 43.4 [32.0-55.7] years) met the inclusion criteria. RRM was associated with lower all-cause mortality compared with MRI-based screening (HR, 0.37; 95% CI, 0.22-0.63) and mammography alone (HR, 0.16; 95% CI, 0.08-0.32). RRM was also associated with lower breast cancer-specific mortality compared with mammography alone (HR, 0.07; 95% CI, 0.01-0.44) but did not have significantly lower mortality than MRI-based screening (HR, 0.26; 95% CI, 0.05-1.35). In BRCA1-only analyses, RRM was associated with lower breast cancer-specific mortality compared with MRI-based screening (HR, 0.13; 95% CI, 0.03-0.66) and mammography alone (HR, 0.03; 95% CI, 0.00-0.15). SUCRA rankings indicated RRM had the highest likelihood of association with the lowest all-cause mortality (SUCRA value, 99.9%). Risk of bias was critical for 4 studies, and certainty of evidence was rated as very low for all 5 studies. CONCLUSIONS AND RELEVANCE: In this systematic review and network meta-analysis of RRSO-adjusted analyses, RRM was associated with lower all-cause mortality compared with breast cancer screening among females with PVs in BRCA1 and BRCA2, with the greatest magnitude of association for breast cancer-specific mortality observed in BRCA1 PV carriers. These findings provide less confounded survival estimates to support individualized shared decision-making for RRM. PMID: 42961418 | DOI: 10.1001/jamanetworkopen.2026.41231
引用
- PubMed 高证据 · 乳腺影像:Survival After Risk-Reducing Mastectomy in Patients With Pathogenic Variants in BRCA1 and BRCA2: A Network Meta-Analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。